BIOCARTIS LAUNCHES EQUITY PLACEMENT
Mechelen, Belgium, 23 January 2019 - Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today the launch of an equity offering to raise an amount of approximately EUR 45 million by means of a private placement via an accelerated bookbuild offering (the "Offering").
Biocartis currently envisages using the net proceeds to fund the expansion of the Idylla(TM) test menu and applications, its sales and marketing activities, further investments in its cartridge manufacturing capacity, and for working capital and other general corporate purposes.
The accelerated bookbuilding procedure will commence immediately. The Company will announce the results of the Offering as soon as possible after closing of the bookbuilding in a subsequent press release.
Trading in Biocartis shares on Euronext Brussels will be suspended during the bookbuilding period. Trading in the stock is expected to resume following the publication of the results of the Offering.
Joh. Berenberg, Gossler & Co. KG ("Berenberg"), KBC Securities SA/NV ("KBC Securities") and Kempen & Co N.V. ("Kempen") are acting as Joint Bookrunners in the Offering.
In relation to the Offering, the Company has agreed with the Joint Bookrunners to a market customary 90 days standstill period on future share issuances, waivable by the Joint Bookrunners subject to customary exceptions.